home.aspx

 
.

BIOPHARMA DEAL MAKING: LESSONS LEARNT FROM CASS BUSINESS SCHOOL’S STUDY OF STRATEGIC DEALS AND CORPORATE PORTFOLIO MANAGEMENT

Extensive prior studies have shown strong positive effects for targets and negative effects for acquirers but, they have focused on measuring value creation from individual deals, not a firm’s overall programs of activity and performance over longer time periods. This far reaching study analyzed over 20 years of data from 25,000+ global firms and 265,000+ deals.